Building on Cyclotek’s original 2017 agreement with Duchembio Co. Ltd., Cyclotek now holds rights to commercialise [18F]FP-CIT in Australia, New Zealand, Singapore, Malaysia, Indonesia, India, and Vietnam. This expansion enhances access to a critical diagnostic tool for clinicians and patients throughout the Asia-Pacific region, where demand for advanced neuroimaging continues to grow.
The updated license also incorporates recent advances in production, including a new precursor formulation and improved purification processes, ensuring a reliable and scalable supply of [18F]FP-CIT across the licensed territory.
Greg Santamaria, CEO of Cyclotek, commented, “Expanding access to [18F]FP-CIT across these emerging markets underscores our commitment to improving diagnostic capabilities for neurodegenerative diseases. These advancements not only strengthen our manufacturing capabilities but also broaden availability for patients and healthcare providers.”
Across the Asia-Pacific region, access to advanced radiopharmaceutical diagnostics remains variable, shaped by differences in infrastructure, regulatory pathways, and reimbursement systems. Expanding availability of [18F]FP-CIT helps address these disparities by supporting more consistent access to high-quality imaging, enabling earlier and more accurate diagnosis of neurodegenerative diseases across both developed and emerging markets.
Steve Kim, CEO of Duchembio explained, “[18F]FP-CIT PET imaging is a valuable tool in differentiating Parkinson’s disease from non-Parkinsonian tremors, enabling earlier and more accurate diagnosis, an essential step in effective patient care and disease management. Duchembio is delighted to continue and expand the licensing partnership with Cyclotek based on its proprietary technologies to improve the production efficiency for [18F]FP-CIT.”
For further information, please contact: Mr Greg Santamaria – enquiries@cyclotek.com
About Cyclotek
Cyclotek is the leading radiopharmaceutical manufacturer in Australia and New Zealand. We manufacture diagnostic and therapeutic radiopharmaceuticals for supply into clinical trials and for clinical use.
At Cyclotek, we are committed to improving patient outcomes by making diagnostic and therapeutic radiopharmaceuticals accessible. PET tracers provide patient specific insights into their disease state, leading to earlier diagnosis, more accurate assessment of disease extent, and improved treatment planning and monitoring. Paired with radionuclide therapies, these products offer a comprehensive, non-invasive disease management option.
Our dedication to innovation drives our continuous development of new radiopharmaceuticals. This helps provide our customers a growing range of tools that enhance the understanding of each patient’s health, contributing to more cost-effective healthcare solutions.
At Cyclotek, we are not just a manufacturer, we are a hub of innovation. Our commitment to quality, safety, supply and customer service ensures that healthcare providers have the best tools available for precise diagnostics and therapies, fostering improved patient care.
Through our unwavering focus on excellence, we aim to make a lasting, positive impact on healthcare.
About DuChemBio Co., Ltd.
Established in 2002, DuChemBio is the largest radiopharmaceutical firm and the undisputed leader in the field of oncology and neurology PET imaging tracers in South Korea. As a pioneer of a fully integrated nuclear diagnostics business model, DCB develops, manufactures, and commercializes radiopharmaceutical tracers for PET/CT and PET/MRI hybrid imaging.
After the merger with Carecamp Inc in 2021, the company now operates 12 radio-pharmacy facilities across the country. DCB is closely collaborating with leading hospitals and research centres to develop and advance the field of nuclear medicine in South Korea. DCB has successfully launched novel proprietary radiopharmaceutical products both developed locally and licensed from international partners.
[contact-form-7 id=”714″ title=”Update Form”]
